Terms: = Germ cell tumor AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Treatment
447 results:
1. Effects of schisandrin B on hypoxia-related cognitive function and protein expression in vascular dementia rats.
He JB; Zhang H; Zheng HX; Jia JX; Zhang YC; Yan XS; Li XX; Wei KW; Mao J; Chen H; Li J; Wang H; Zhang M; Zhao ZY
J Toxicol Environ Health A; 2024 May; 87(10):421-427. PubMed ID: 38551405
[TBL] [Abstract] [Full Text] [Related]
2. Development of a vestibular schwannoma tumor slice model for pharmacological testing.
Nickl V; Fakler J; Ziebolz D; Rumpel C; Stabenow L; Bernhagen J; Rampeltshammer E; Ernestus RI; Löhr M; Gugel I; Matthies C; Monoranu CM; Hagemann C; Breun M
J Neurosci Methods; 2024 May; 405():110082. PubMed ID: 38387803
[TBL] [Abstract] [Full Text] [Related]
3. Imaging as an early biomarker to predict sensitivity to everolimus for progressive nf2-related vestibular schwannoma.
Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
[TBL] [Abstract] [Full Text] [Related]
4. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Nagel A; Huegel J; Petrilli A; Rosario R; Victoria B; Hardin HM; Fernandez-Valle C
Oncogene; 2024 Mar; 43(13):921-930. PubMed ID: 38336988
[TBL] [Abstract] [Full Text] [Related]
5. Functional interactions between neurofibromatosis tumor suppressors underlie schwann cell tumor de-differentiation and treatment resistance.
Vasudevan HN; Payne E; Delley CL; John Liu S; Mirchia K; Sale MJ; Lastella S; Nunez MS; Lucas CG; Eaton CD; Casey-Clyde T; Magill ST; Chen WC; Braunstein SE; Perry A; Jacques L; Reddy AT; Pekmezci M; Abate AR; McCormick F; Raleigh DR
Nat Commun; 2024 Jan; 15(1):477. PubMed ID: 38216572
[TBL] [Abstract] [Full Text] [Related]
6. Stereotactic Radiosurgery and Radiotherapy for Vestibular schwannoma in nf2-Related schwannomatosis.
Shrivastava M; Emmanouil B; Mathew R; Halliday D; Parry A; Halliday J; Mackeith S
Laryngoscope; 2024 May; 134(5):2364-2371. PubMed ID: 37983868
[TBL] [Abstract] [Full Text] [Related]
7. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract] [Full Text] [Related]
8. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
[TBL] [Abstract] [Full Text] [Related]
9. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
Staedtke V; Anstett K; Bedwell D; Giovannini M; Keeling K; Kesterson R; Kim Y; Korf B; Leier A; McManus ML; Sarnoff H; Vitte J; Walker JA; Plotkin SR; Wallis D
Clin Trials; 2024 Feb; 21(1):51-66. PubMed ID: 37937606
[TBL] [Abstract] [Full Text] [Related]
10. Sporadic vestibular schwannoma in a pediatric population: a case series.
Kosaraju N; Moore LS; Mulders JY; Blevins NH
Childs Nerv Syst; 2024 Mar; 40(3):635-645. PubMed ID: 37889276
[TBL] [Abstract] [Full Text] [Related]
11. New classification and approaches to the treatment of schwannomatosis.
Makashova ES; Zolotova SV; Absalyamova OV; Galkin MV; Petrokovskaya AV; Kozlov AV; Golanov AV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(5):104-109. PubMed ID: 37830475
[TBL] [Abstract] [Full Text] [Related]
12. schwannomatosis: a Realm Reborn: year one.
Planet M; Kalamarides M; Peyre M
Curr Opin Oncol; 2023 Nov; 35(6):550-557. PubMed ID: 37820090
[TBL] [Abstract] [Full Text] [Related]
13. [schwannoma, Neurofibromatosis Type 2, and schwannomatosis in the 2021 WHO Classification of tumors of the Central Nervous System].
Nagai K; Fujii M
No Shinkei Geka; 2023 Sep; 51(5):845-857. PubMed ID: 37743336
[TBL] [Abstract] [Full Text] [Related]
14. Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients.
Puataweepong P; Dhanacha M; Ruangkanchanasetr R; Boonyawan K; Hansasuta A; Saetia K; Yongvithisatid P
J Neurooncol; 2023 Sep; 164(3):587-595. PubMed ID: 37702975
[TBL] [Abstract] [Full Text] [Related]
15. Longitudinal Performance of Cochlear Implants in Neurofibromatosis Type 2.
Seo S; Shen S; Ding AS; Creighton FX
Laryngoscope; 2024 Apr; 134(4):1847-1853. PubMed ID: 37698390
[TBL] [Abstract] [Full Text] [Related]
16. Fractionated Stereotactic Radiotherapy Compared to Stereotactic Radiosurgery for Vestibular schwannoma in Patients with Type 2 Neurofibromatosis.
Mauro GP; Da Róz LM; Gico VC; Weltman E; César de Souza E; Figueiredo EG; Teixeira MJ
World Neurosurg; 2023 Nov; 179():e416-e420. PubMed ID: 37657590
[TBL] [Abstract] [Full Text] [Related]
17. schisandrin B Inhibits cell Viability and Malignant Progression of Melanoma cells
Chen J; Zhang L; Pu Y; Chen Y; Li Y; Pan X; Chen J
Anticancer Agents Med Chem; 2023; 23(15):1765-1773. PubMed ID: 37622448
[TBL] [Abstract] [Full Text] [Related]
18. Hearing Rehabilitation in Patients With Neurofibromatosis Type 2: The Quebec's Experience With Auditory Implants.
Khneisser E; Bussieres R; Côté M; Philippon D; Fradet G; Côté M; Lessard N; Champagne PO; Trudel M
Otol Neurotol; 2023 Sep; 44(8):e621-e627. PubMed ID: 37550875
[TBL] [Abstract] [Full Text] [Related]
19. CP-GEP (merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?
Quattrocchi E; Meves ES; Meves A
Ital J Dermatol Venerol; 2023 Aug; 158(4):292-301. PubMed ID: 37539500
[TBL] [Abstract] [Full Text] [Related]
20. The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.
Presciutti AM; Lester EG; Woodworth EC; Greenberg J; Bakhshaie J; Hooker JE; McDermott KA; Vranceanu AM
J Neurooncol; 2023 Jul; 163(3):707-716. PubMed ID: 37440099
[TBL] [Abstract] [Full Text] [Related]
[Next]
